Zyprexa Under Medicare: Shift From Medicaid Means $200 Mil. Less Rebates
Executive Summary
The transfer of "dual eligible" Zyprexa patients from Medicaid to the new Medicare drug benefit means that Lilly's rebate payments to states will be reduced by about $200 mil. per year
You may also be interested in...
Antipsychotic Medicare Prices Are 15%-30% Off AWP; Abilify Is Outlier
Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole) is being offered at less than half of list price under the National Community Pharmacy Association's Medicare-endorsed discount card brands
Antipsychotic Medicare Prices Are 15%-30% Off AWP; Abilify Is Outlier
Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole) is being offered at less than half of list price under the National Community Pharmacy Association's Medicare-endorsed discount card brands
Neurontin Off-Label Use Needs Prior Authorization Under Fla. Medicaid Plan
Prior authorization for off-label use of Pfizer's Neurontin would save the Florida Medicaid program $7 mil., the FY 2004-2005 budget proposal states